Special Issue

Impact of 3'UTR Variants on mRNA Stability

Message from the Guest Editors

In this Special Issue we are interested in the mechanisms that generate 3'UTR diversity in normal and disease cells (such as alternative polyadenylation, alternative splicing, or the exonization of repetitive elements), in addition to their impact on mRNA function. Furthermore, we are also especially interested in the use of alternative 3'UTRs for the stabilization of mRNA vaccines.We are also willing to receive originals on technical developments that have facilitated the generation as well as analysis of transcriptonic information of 3'UTR variants and their impact on mRNA stability and function:Development of software to extract variant 3'UTR data from RNA.seq/single-cell RNA.seq runs;
Generation of databases of variant 3'UTRs in human diseases;
New experimental techniques for the high-throughput targeting of mRNA–miRNA as well as miRNA–lncRNA interactions;
Software for modeling mRNA–miRNA–lncRNA networks, including alternative 3'UTRs

Guest Editors

Dr. Estanislao Navarro

Experimental Nephrology Lab, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, C/ Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907 Barcelona, Spain

Dr. Miguel Hueso

Department of Nephrology, Hospital Universitari de Bellvitge, 08907 L'Hospitalet de Llobregat, Spain

Deadline for manuscript submissions

closed (31 January 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/162285

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).